Mitofusin Gene Mutation Detection for CMT2A Diagnosis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for diagnosing Charcot-Marie-Tooth Disease Type 2A are inadequate, as they rely on identifying mutations in the KIF1B gene, which are not present in all affected families, highlighting the need for an alternative diagnostic approach.
Innovation Solution
The method involves detecting mutations in the mitofusin gene, specifically amplifying the mitofusin gene sequence from a biological sample and identifying associated polymorphisms to determine the risk or presence of Charcot-Marie-Tooth Disease Type 2A, using techniques such as PCR and sequencing to diagnose the disease or predisposition.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If diagnostic methods rely on identifying mutations in the KIF1B gene, then diagnosis can be performed for families with KIF1B mutations, but the method fails to diagnose affected families without KIF1B mutations
Solution Approach 1:
The patent shifts from a gene-specific diagnostic approach (KIF1B only) to a locus-based approach that can identify multiple genes within the CMT2A chromosomal region. This universal method allows the same diagnostic procedure to detect mutations in any gene located at 1p35-36, making it applicable to all CMT2A families regardless of which specific gene is mutated.
Solution Approach 2:
The patent divides the CMT2A diagnostic approach into two components: (1) chromosomal localization to identify the CMT2A locus at 1p35-36 using linkage analysis or other genetic mapping techniques, and (2) subsequent mutation screening of candidate genes within that localized region. This segmentation allows systematic identification of mutations in any gene within the locus.
2Ease of manufacture
If only KIF1B gene mutations are screened, then the diagnostic process is simple and focused, but many CMT2A cases are missed
Solution Approach 1:
The patent performs preliminary chromosomal localization to identify the CMT2A locus before conducting mutation screening. By first establishing that the patient's condition links to the 1p35-36 region through linkage analysis or genetic mapping, the diagnostic process pre-identifies the relevant chromosomal segment, making subsequent gene-specific mutation screening more efficient and comprehensive.
Data Source
AI summary
Methods are described for screening a subject for risk of Charcot-Marie-Tooth Disease Type 2A or for diagnosing Charcot-Marie-Tooth disease or a predisposition for developing Charcot-Marie-Tooth disease in a subject, by detecting the presence or absence of a mutation in the mitofusin gene in a biological sample collected from the subject. Methods are also described for detecting the presence of a genetic polymorphism associated with Charcot-Marie-Tooth Disease Type 2A in a sample of patient nucleic acid, by amplifying a mitofusin gene sequence in the patient nucleic acid to produce an amplification product; and identifying the presence of a Charcot-Marie-Tooth Disease Type 2A associated polymorphism in the amplification product.